The workup for immune thrombocytopenia starts with two simple tests and expands outward based on what those results show. A complete blood count and a peripheral blood smear form the bare minimum, but because ITP has no single confirmatory test, the real work lies in ruling out the many other conditions that can cause a low platelet count. A platelet count below 100 × 10⁹/L is the key threshold, though the count alone is never enough to make the diagnosis.1PubMed Central. Advances in Diagnosis and Treatments for Immune Thrombocytopenia How far your doctor takes the workup depends on your age, symptoms, medical history, and how confident they are after looking at those first results.
The Starting Point: Blood Count and Smear
Every ITP workup begins with a complete blood count (CBC) and a peripheral blood smear. The CBC tells your doctor the platelet number and confirms that your red blood cells and white blood cells look normal in quantity. In ITP, the platelet count is low but everything else is typically fine. If other cell lines are also abnormal, the diagnosis shifts toward something else entirely, like a bone marrow disorder or a nutritional deficiency.
The peripheral blood smear is where a trained eye examines your blood cells under a microscope. In ITP, you expect to see a small number of large platelets with otherwise normal-looking cells. The smear rules out several mimics at a glance. Clumped platelets suggest pseudothrombocytopenia, a lab artifact where anticoagulant in the blood collection tube causes platelets to stick together, giving a falsely low count. Fragmented red blood cells called schistocytes point toward conditions like thrombotic thrombocytopenic purpura (TTP) or hemolytic uremic syndrome. Abnormal white blood cells, such as blast cells, raise concern for leukemia. Giant or oddly colored platelets can flag inherited platelet disorders rather than ITP.2PubMed Central. Primary immune thrombocytopenia: a ‘diagnosis of exclusion’? The smear is quick, cheap, and enormously informative. If the smear looks reassuring and the CBC shows isolated low platelets, your doctor already has reason to suspect ITP, but confirming it requires chasing down the list of conditions that can look identical.
Why a Drug History Matters More Than You’d Expect
Drug-induced thrombocytopenia (DITP) can be clinically indistinguishable from primary ITP, and it is frequently overlooked.3Transfusion Medicine Reviews. Approach to the Diagnosis and Management of Drug-Induced Immune Thrombocytopenia The platelet count drops, the blood smear looks similar, and if nobody asks the right questions about medications, the wrong diagnosis sticks. A thorough drug history is not just a formality. It should cover prescription medications, over-the-counter drugs, herbal supplements, and even certain foods and beverages.
The classic pattern is a new medication started one to two weeks before the platelet count falls. Some drugs, though, can trigger immediate drops after a single dose, particularly certain anti-clotting agents used in hospital settings. Five clinical criteria help clinicians sort out DITP: exposure to a new drug in the right time window, platelet recovery after stopping the drug, a sustained normal count when other medications are continued, exclusion of other causes, and recurrence if the drug is reintroduced.4Haematologica. Treatment of drug-induced immune thrombocytopenias In practice, applying those criteria gets messy when a patient takes multiple medications and has other conditions that could lower platelets on their own. Still, recovery from DITP usually begins within a day or two of stopping the offending drug and is typically complete within a week, which is itself a useful diagnostic clue.5PubMed Central. Drug-induced thrombocytopenia: pathogenesis, evaluation, and management
Screening for Infections That Can Cause or Worsen ITP
Several infections are known to trigger secondary ITP, and identifying them changes treatment entirely. HIV and hepatitis C (HCV) are the big two. Both can cause isolated thrombocytopenia that looks exactly like primary ITP, and both should always be suspected in patients at risk who present with low platelet counts.6Taylor & Francis Online (Expert Review of Hematology). Thrombocytopenia and infections Treating the underlying infection often improves the platelet count without any ITP-specific therapy, so missing the infection means subjecting a patient to unnecessary immunosuppressive treatment. HIV and HCV testing is standard in the adult ITP workup.
Helicobacter pylori, the stomach bacterium best known for causing ulcers, has a well-documented relationship with ITP. Eradicating the infection raises platelet counts in a substantial proportion of infected ITP patients, and in many responders, the effect is durable. One study found that the anti-platelet autoimmune response completely resolved after H. pylori treatment, with no relapse for more than seven years in the majority of responders.7PubMed Central. Helicobacter pylori-associated immune thrombocytopenia: clinical features and pathogenic mechanisms Another study showed that patients whose H. pylori was successfully eradicated maintained roughly a two- to threefold increase in platelet counts above their baseline during follow-up, compared with more modest gains in patients who still had the infection or were never infected.8Scientific Reports. Helicobacter pylori eradication affects platelet count recovery in immune thrombocytopenia Current guidelines recommend that adult patients with suspected ITP be tested for H. pylori, and if the infection is present, eradication therapy should be given before committing to more aggressive ITP treatments.
Epstein-Barr virus (EBV) and cytomegalovirus (CMV) have also been linked to ITP, though their role is less well-defined. In one study, about a fifth of ITP patients had active EBV and a similar proportion had CMV, compared with almost none in the control group.9PubMed. The role of Epstein-Barr virus (EBV) and cytomegalovirus (CMV) in immune thrombocytopenia Another study of acute ITP patients found CMV DNA in a quarter and EBV DNA in a smaller fraction, with significantly higher rates than in healthy controls.10PubMed Central. Prevalence of Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) Subclinical Infection in Patients with Acute Immune Thrombocytopenic Purpura (ITP) Testing for these viruses is not universally performed as part of a first-line workup the way HIV and HCV testing are, but your doctor may order it depending on your clinical picture and geographic risk factors.
Autoimmune Screening and Why It Matters for Prognosis
ITP can be the first sign of a broader autoimmune condition, so part of the workup involves looking for evidence that the immune system is attacking more than just platelets. Antinuclear antibody (ANA) testing is one of the most commonly ordered screens. A positive ANA in someone with ITP does not mean they have lupus, but it flags a higher risk. One large study found that ANA-positive ITP patients had roughly nine times the risk of developing a connective tissue disease during follow-up compared with ANA-negative patients. About 4% of ANA-positive ITP patients later developed lupus, while none of the ANA-negative patients did.11PubMed Central. ANA-positive primary immune thrombocytopaenia: a different clinical entity with increased risk of connective tissue diseases This matters for surveillance: a positive ANA means your doctor should be keeping an eye on you for emerging autoimmune symptoms over the coming years.
Antiphospholipid antibodies are checked for similar reasons. ITP patients who carry these antibodies face an increased risk of blood clots, and that risk may climb further with certain ITP treatments such as thrombopoietin receptor agonists, the drugs used to stimulate platelet production.12Hematology Am Soc Hematol Educ Program. How do we diagnose immune thrombocytopenia in 2018? Knowing about antiphospholipid antibodies upfront shapes treatment choices in a concrete way.
Thyroid function tests are another part of the picture that doctors sometimes overlook. The prevalence of thyroid dysfunction in ITP patients runs around a quarter, far higher than in the general population. One study found overt hypothyroidism in about 16% of ITP patients and subclinical hypothyroidism in another 7%, with anti-thyroid antibodies associated with chronic ITP.13PubMed Central. Thyroid Dysfunction in Patients With Immune Thrombocytopenia: Prevalence and it’s Impact On Outcome Some experts recommend checking thyroid function in every ITP patient, and there is particular reason to do so in patients who do not respond well to steroids, since untreated thyroid disease can undermine the response to corticotherapy.14PubMed Central. Immune thrombocytopenia and autoimmune thyroid disease: a controversial overlap
Immunoglobulin Levels and Common Variable Immunodeficiency
A test that often gets left off the list is a check of immunoglobulin levels (IgG, IgA, IgM). This screens for common variable immunodeficiency (CVID), an immune disorder in which the body fails to produce enough protective antibodies. The connection matters because ITP frequently shows up before CVID is diagnosed, meaning the low platelet count may be the first visible sign of a deeper immune defect. For this reason, immunoglobulin testing has been recommended for every patient diagnosed with autoimmune thrombocytopenia.15Medicine. Autoimmune Thrombocytopenic Purpura and Common Variable Immunodeficiency Missing a CVID diagnosis has real consequences: patients with CVID need immunoglobulin replacement therapy and careful monitoring for infections and other autoimmune complications, and immunosuppressive ITP treatments can make their underlying immune deficiency worse.
When a Bone Marrow Biopsy Is and Isn’t Needed
One of the most common questions patients have is whether they will need a bone marrow biopsy. The short answer for most younger patients with a typical presentation is no. Research shows that routine bone marrow examination is not required in the diagnostic workup of isolated thrombocytopenia, provided that the history, physical exam, blood count, and smear are all consistent with ITP.16PubMed Central. Re-evaluation of Need for Bone Marrow Examination in Patients with Isolated Thrombocytopenia This is a change from older practice, when a marrow biopsy was nearly automatic before starting steroid treatment.
The picture changes in older adults. Conditions like myelodysplastic syndrome (MDS) and low-grade blood cancers can initially mimic ITP with nothing more than an isolated low platelet count. A bone marrow biopsy may be the only tool that distinguishes ITP from these disorders, and it is recommended in elderly patients where the suspicion for an indolent hematological malignancy exists.17Blood. The Importance of a Bone Marrow Biopsy to Distinguish Primary Immune Thrombocytopenia From Indolent Haematological Malignancies Beyond age, other factors that make a biopsy more likely include male sex, a very low baseline platelet count, failure of initial treatments, and consideration of splenectomy.18PubMed. Predictors for and outcomes after bone marrow biopsy in Scandinavian patients with chronic immune thrombocytopenia If your doctor brings up a bone marrow biopsy, it does not mean they think you have cancer. It means your clinical profile has features that warrant ruling out conditions the blood tests alone cannot exclude.
Specialized Lab Tests and Their Limits
Two specialized tests come up in the ITP workup, and neither is a straightforward yes-or-no tool.
Platelet autoantibody testing looks for antibodies stuck to the surface of your platelets or circulating in your blood. A positive result strongly supports the diagnosis of ITP, because these tests have high specificity. The problem is sensitivity: a meta-analysis of the available evidence found that a negative result does not rule ITP out.19Journal of Thrombosis and Haemostasis. Diagnostic accuracy of platelet autoantibody testing in immune thrombocytopenia: A systematic review and meta-analysis When researchers applied strict diagnostic criteria and looked specifically at patients with well-established ITP, sensitivity improved to roughly 65%, but specificity dipped somewhat.20PubMed. Performance characteristics of platelet autoantibody testing for the diagnosis of immune thrombocytopenia using strict clinical criteria The low sensitivity likely reflects the fact that ITP is driven by multiple immune mechanisms, not just autoantibodies. So a positive test is helpful; a negative test tells you relatively little. This is why autoantibody testing is not universally recommended as a first-line test and is typically reserved for cases where the diagnosis remains uncertain after the standard workup.
Serum thrombopoietin (TPO) levels offer a different angle. TPO is the hormone that tells your bone marrow to make more platelets. In ITP, TPO levels tend to be only mildly elevated, because the marrow is actually producing plenty of platelets, it’s just that the immune system is destroying them faster than they can survive. In aplastic anemia, where the marrow itself is failing, TPO levels are dramatically higher. One study found that TPO could distinguish ITP from aplastic anemia with roughly 81% sensitivity and 94% specificity, making it a promising noninvasive alternative to bone marrow biopsy in some situations.21PubMed Central. Assessing serum thrombopoietin for enhanced diagnosis of ITP, AA, and MDS using machine learning: A retrospective cohort study Earlier work confirmed the same basic pattern: TPO in ITP patients runs mildly above normal, while in aplastic anemia it skyrockets.22PubMed. Circulating thrombopoietin level in chronic immune thrombocytopenic purpura TPO testing is not part of every standard workup, but it can be useful when the question is whether the low platelets stem from destruction (as in ITP) or from inadequate production.
How the Workup Differs in Children Versus Adults
ITP in children is generally a different animal than in adults. Childhood ITP often follows a viral infection, tends to be acute and self-resolving, and usually requires a less extensive workup. An international registry comparing children and adults with newly diagnosed ITP found that bone marrow examinations, ANA testing, and HIV and hepatitis C screening were all performed far more frequently in adults than in children.23Haematologica. Newly diagnosed immune thrombocytopenia in children and adults: a comparative prospective observational registry of the Intercontinental Cooperative Immune Thrombocytopenia Study Group The reasoning makes sense: children are less likely to have HIV, hepatitis, autoimmune diseases, or bone marrow disorders, so the yield of those tests is lower and the pre-test probability is different.
That said, certain findings push clinicians to dig deeper in children. A positive direct antiglobulin test (DAT), which detects antibodies on red blood cells, has been independently associated with chronic ITP and with needing second-line treatments in pediatric patients.24PubMed. Association of a positive direct antiglobulin test with chronic immune thrombocytopenia and use of second line therapies in children: A multi-institutional review A positive DAT can also signal Evans syndrome, where the immune system attacks both platelets and red blood cells. When a child’s ITP does not resolve within the expected timeframe, the workup tends to expand to resemble an adult evaluation more closely.
Thrombocytopenia During Pregnancy
Pregnancy creates a unique diagnostic challenge because a mild drop in platelet count is common and usually harmless. Gestational thrombocytopenia accounts for the majority of low platelet counts discovered during pregnancy, and by definition it is a benign condition that resolves after delivery. The trouble is that ITP and gestational thrombocytopenia overlap in their lab findings. Both cause isolated low platelets with an otherwise normal blood count.25PubMed Central. The Differential Diagnosis of Thrombocytopenia in Pregnancy
A few clues can help. ITP is more likely when the platelet count drops below about 70,000/μL or when the thrombocytopenia appears in the first trimester, since gestational thrombocytopenia usually shows up later and stays milder. But these patterns are not absolutes. One study found that early onset and counts under 70,000 were “not uncommon” in gestational thrombocytopenia either, and concluded that a definitive distinction between the two may only be possible by watching what happens to the platelet count after delivery.26PubMed. Clinical features of gestational thrombocytopenia difficult to differentiate from immune thrombocytopenia diagnosed during pregnancy If the count normalizes within a few weeks postpartum, it was likely gestational. If it stays low, ITP becomes the leading diagnosis and a full workup is warranted.
Genetic Testing for Chronic ITP That Doesn’t Behave as Expected
A newer addition to the ITP workup is genetic sequencing, aimed at patients whose chronic ITP resists standard treatments or whose presentation raises suspicion of an inherited platelet disorder masquerading as ITP. A recent study found that roughly one in ten patients referred with a diagnosis of chronic ITP actually carried a known disease-causing genetic variant, and about a third had variants of uncertain significance.27Blood Advances. The role of genetic sequencing in the diagnostic workup for chronic immune thrombocytopenia The practical consequences of finding these variants are significant. Some inherited platelet disorders respond poorly or not at all to immunosuppressive therapy, which is the backbone of ITP treatment. Identifying the variant can steer patients away from treatments that won’t work and toward ones that might, including, in rare cases, stem cell transplantation.
Genetic testing is not yet standard for everyone diagnosed with ITP. It is most useful in patients with chronic disease that does not respond to usual treatments, a family history of low platelet counts, or atypical features on the blood smear that hint at an inherited condition. As sequencing costs continue to fall, this test may become more routine in the chronic ITP workup.
Putting the Pieces Together
No single test confirms ITP. The diagnosis comes from assembling a coherent picture: isolated low platelets, a reassuring blood smear, a clean drug history, negative infectious screens, no evidence of a broader autoimmune disease, and no signs of marrow failure. The 2019 international consensus report reflects this reality by framing ITP evaluation as a layered process, beginning with basic labs and expanding into additional testing based on clinical context.28PubMed Central. Updated international consensus report on the investigation and management of primary immune thrombocytopenia
In practice, this means the extent of your workup depends on who you are. A healthy 25-year-old with sudden-onset bruising, a platelet count of 15,000, and an unremarkable blood smear may need only a CBC, smear, HIV test, HCV test, and possibly H. pylori screening before starting treatment. A 68-year-old with a gradual decline in platelets, mild anemia, and some large platelets on the smear will likely get a broader panel including ANA, thyroid function, immunoglobulin levels, and a bone marrow biopsy. Neither workup is wrong. The evidence supports matching the depth of testing to the clinical probability of alternative diagnoses, rather than running the same battery on every patient.29PubMed Central. Assessment and Management of Immune Thrombocytopenia (ITP) in the Emergency Department: Current Perspectives If your workup felt quick, that is usually a sign your presentation was straightforward. If it felt extensive, your doctor was being thorough in protecting you from a missed diagnosis that could change everything about your care.